AI Article Synopsis
- Murepavadin is a new drug that targets a specific protein in a multidrug-resistant Gram-negative pathogen, which is known to cause serious lung infections.
- The study shows that murepavadin boosts the effectiveness of ciprofloxacin, a common antibiotic, by increasing its levels inside the bacterial cells and reducing its expulsion.
- The combination of murepavadin and ciprofloxacin works well together in treating pneumonia in mice, suggesting that it could be a promising option for tackling difficult infections in humans.
Article Abstract
is a multidrug-resistant Gram-negative pathogen and one of the leading causes of ventilator-associated pneumonia and infections in patients with chronic obstructive pulmonary disease and cystic fibrosis. Murepavadin is a peptidomimetic that specifically targets outer-membrane lipopolysaccharide transport protein LptD of . In this study, we find that murepavadin enhances the bactericidal efficacy of ciprofloxacin. We further demonstrate that murepavadin increases intracellular accumulation of ciprofloxacin by suppressing drug efflux. In addition, the murepavadin-ciprofloxacin combination exhibits a synergistic bactericidal effect in an acute murine pneumonia model. In conclusion, our results identify an effective drug combination for the treatment of infections.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11429200 | PMC |
| http://dx.doi.org/10.3390/antibiotics13090810 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Murepavadin Enhances the Killing Efficacy of Ciprofloxacin against by Inhibiting Drug Efflux.
Antibiotics (Basel)
August 2024
State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Molecular Microbiology and Technology of the Ministry of Education, Department of Microbiology, College of Life Sciences, Nankai University, Tianjin 300071, China.
Article Synopsis
- Murepavadin is a new drug that targets a specific protein in a multidrug-resistant Gram-negative pathogen, which is known to cause serious lung infections.
- The study shows that murepavadin boosts the effectiveness of ciprofloxacin, a common antibiotic, by increasing its levels inside the bacterial cells and reducing its expulsion.
- The combination of murepavadin and ciprofloxacin works well together in treating pneumonia in mice, suggesting that it could be a promising option for tackling difficult infections in humans.
Murepavadin promotes the killing efficacies of aminoglycoside antibiotics against by enhancing membrane potential.
Antimicrob Agents Chemother
April 2024
State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Molecular Microbiology and Technology of the Ministry of Education, Department of Microbiology, College of Life Sciences, Nankai University, Tianjin, China.
Murepavadin is a peptidomimetic that specifically targets the lipopolysaccharide transport protein LptD of . Here, we found that murepavadin enhances the bactericidal efficacies of tobramycin and amikacin. We further demonstrated that murepavadin enhances bacterial respiration activity and subsequent membrane potential, which promotes intracellular uptake of aminoglycoside antibiotics.
View Article and Find Full Text PDFAntibiotic therapy for nonfermenting Gram-negative bacilli infections: future perspectives.
Curr Opin Infect Dis
December 2023
Infectious Diseases Unit, Policlinico San Martino Hospital - IRCCS.
Article Synopsis
- Serious infections from nonfermenting Gram-negative bacteria (NF-GNB) are hard to treat due to limited effective options and significant side effects.
- Recent studies highlight promising new drugs in development, such as Durlobactam-sulbactam and cefepime-taniborbactam, which could combat resistant strains like Acinetobacter baumannii.
- Overall, these novel treatments show potential effectiveness against NF-GNB and may be useful future therapies, though further research is needed, particularly concerning their safety.
Murepavadin induces envelope stress response and enhances the killing efficacies of β-lactam antibiotics by impairing the outer membrane integrity of .
Microbiol Spectr
September 2023
State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Molecular Microbiology and Technology of the Ministry of Education, Department of Microbiology, College of Life Sciences, Nankai University, Tianjin, China.
is a ubiquitous opportunistic pathogen that can cause a variety of acute and chronic infections. The bacterium is highly resistant to numerous antibiotics. Murepavadin is a peptidomimetic antibiotic that blocks the function of lipopolysaccharide (LPS) transport protein D (LptD), thus inhibiting the insertion of LPS into the outer membrane.
View Article and Find Full Text PDFCurrent and Emerging Inhaled Antibiotics for Chronic Pulmonary and Infections in Cystic Fibrosis.
Antibiotics (Basel)
February 2023
Department of Biochemistry & Pharmacology, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, VIC 3010, Australia.
Characterized by impaired mucus transport and subsequent enhanced colonization of bacteria, pulmonary infection causes major morbidity and mortality in patients with cystic fibrosis (CF). () and () are the two most common types of bacteria detected in CF lungs, which undergo multiple adaptational mechanisms such as biofilm formation resulting in chronic pulmonary infections. With the advantages of greater airway concentration and minimized systemic toxicity, inhaled antibiotics are introduced to treat chronic pulmonary infection in CF.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!